Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:27 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 38,040 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0002049287-26-000003 · form4-06152026_090634.xml · derivative · entry 1 Zhao Baiteng · CIK 0002049287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,040 Underlying: Common Stock · 38,040 shares Expires 2036-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 00:10 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 40,006 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-25-017620 · form4-06182025_120641.xml · derivative · entry 1 Zhao Baiteng · CIK 0002049287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,006 Underlying: Common Stock · 40,006 shares Expires 2035-06-17 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2026 or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2025. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 23:14 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantCommon Stock | 1,250,000 | $2.40 | $3,000,000.00 |
DisclosureSEC source: 0001415889-25-006682 · form4-03042025_110310.xml · nonDerivative · entry 1 Zhao Baiteng · CIK 0002049287 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,250,000 F1 · ownership.nature: Shares held by WZCUBE LLC. The Reporting Person is the sole manager of WZCUBE LLC. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 22:36 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 61,192 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001415889-24-030096 · form4-12232024_101210.xml · derivative · entry 1 Zhao Baiteng · CIK 0002049287 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,192 Underlying: Common Stock · 61,192 shares Expires 2034-12-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one-thirty-sixth (1/36th) of the shares subject to the option shall vest monthly following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, the last day of the month), such that the option will be fully vested and exercisable three (3) years from the Date of Grant. "Date of Grant" shall mean December 19, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.